BRUKINSA Phase 3 Trial Shows Chemotherapy-Free Promise for Frontline Mantle Cell Lymphoma
BeOne Medicines Ltd. has announced positive topline findings from its pivotal Phase 3 MANGROVE clinical trial, marking a significant milestone in the treatment of newly diagnosed mantle cell lymphoma (MCL). The study demonstrated that a chemotherapy-free combination of BRUKINSA® (zanubrutinib) and rituximab significantly improved progression-free survival compared with the long-standing standard treatment of bendamustine plus rituximab (BR).
The results position BRUKINSA as a potential new frontline treatment option for patients with previously untreated mantle cell lymphoma, offering the possibility of effective disease control without the need for conventional chemotherapy. If approved by regulators, the regimen could redefine the treatment landscape for this aggressive blood cancer while reducing the treatment burden for many patients.
Landmark Phase 3 MANGROVE Trial
The MANGROVE study (BGB-3111-306; NCT04002297) is the first global, randomized Phase 3 clinical trial designed to compare a BTK inhibitor-based chemotherapy-free regimen directly against the current standard chemoimmunotherapy in newly diagnosed mantle cell lymphoma.
The trial enrolled adult patients who had not previously received treatment for MCL. Participants were randomly assigned to receive either:
- BRUKINSA plus rituximab, or
- Bendamustine plus rituximab (BR), the current standard frontline therapy.
Unlike previous studies that combined BTK inhibitors with chemotherapy, MANGROVE evaluated whether chemotherapy could be eliminated entirely while maintaining or improving clinical outcomes.
The study builds upon BRUKINSA’s established clinical profile in mantle cell lymphoma and other B-cell malignancies, extending research into earlier stages of treatment.
Primary Endpoint Successfully Achieved
At the prespecified interim analysis, the trial successfully met its primary endpoint of progression-free survival (PFS).
According to an independent review committee, patients receiving BRUKINSA combined with rituximab experienced a highly statistically significant and clinically meaningful improvement in progression-free survival compared with patients receiving bendamustine plus rituximab.
The data showed:
- A 43% reduction in the risk of disease progression or death.
- Hazard ratio (HR): 0.57
- 95% Confidence Interval: 0.43–0.76
- Statistical significance: p < 0.0001
These results indicate that patients receiving the chemotherapy-free regimen remained free from disease progression substantially longer than those treated with standard chemoimmunotherapy.
The findings represent one of the strongest demonstrations to date that chemotherapy may no longer be necessary as the foundation of first-line treatment for many patients with mantle cell lymphoma.
Potential Shift in Standard of Care
According to BeOne Medicines, the MANGROVE trial has the potential to reshape frontline treatment practices worldwide.
For decades, chemotherapy has remained the default first-line therapy for mantle cell lymphoma despite its well-known toxicities and long-term side effects.
The company believes the study demonstrates for the first time that replacing chemotherapy entirely with a targeted therapy-based regimen can provide superior disease control.
Dr. Amit Agarwal, Chief Medical Officer for Hematology at BeOne Medicines, said the findings could represent a fundamental change in how physicians approach newly diagnosed MCL.
He emphasized that BRUKINSA combined with rituximab produced unprecedented improvements in progression-free survival while eliminating the need for chemotherapy.
He also noted that reducing treatment burden is particularly meaningful for patients, as the chemotherapy-free regimen removes the need for approximately two years of maintenance rituximab infusions that are commonly used after standard treatment.
According to Dr. Agarwal, the study further establishes BRUKINSA as a foundational therapy capable of anchoring frontline treatment across multiple B-cell malignancies.
Eliminating Chemotherapy from Initial Treatment
One of the most notable aspects of the MANGROVE trial is its entirely chemotherapy-free treatment strategy.
Most previous attempts to improve frontline MCL therapy have involved adding BTK inhibitors to chemotherapy rather than replacing chemotherapy altogether.
MANGROVE instead evaluated whether targeted therapy alone could deliver durable disease control while avoiding many of chemotherapy’s well-documented adverse effects.
Patients receiving BRUKINSA plus rituximab also avoided maintenance rituximab therapy, sparing them nearly two years of additional infusion treatments.
This approach has the potential to significantly improve patient convenience while reducing time spent receiving hospital-based therapy.
Safety Profile Remains Consistent
Safety findings from the interim analysis were consistent with the previously established safety profiles of both BRUKINSA and rituximab.
Importantly, investigators reported that no new safety signals emerged during the study.
The overall tolerability observed in MANGROVE aligns with earlier clinical trials evaluating BRUKINSA across several B-cell cancers.
Maintaining a predictable safety profile is particularly important in mantle cell lymphoma, where many patients are older adults who often have additional health conditions that can make intensive chemotherapy difficult to tolerate.
Overall Survival Analysis Continues
Although progression-free survival served as the primary endpoint, overall survival remains an important secondary endpoint in the trial.
At the time of the interim analysis, overall survival data were still immature because patients had not yet been followed long enough for definitive conclusions.
However, investigators reported a favorable trend toward improved overall survival among patients treated with BRUKINSA plus rituximab.
Formal statistical evaluation of overall survival will occur during the study’s final analysis once additional follow-up data become available.
Full Results to Be Presented
BeOne Medicines plans to present the complete findings from the MANGROVE trial at an upcoming international medical conference.
The comprehensive data presentation is expected to include:
- Detailed progression-free survival analyses
- Response rates
- Duration of response
- Safety outcomes
- Subgroup analyses
- Additional efficacy endpoints
These data will provide physicians and researchers with a more complete understanding of the chemotherapy-free regimen’s clinical benefits.
Regulatory Filings Planned
Following the positive topline results, BeOne Medicines has begun discussions with regulatory authorities around the world.
The company plans to submit regulatory applications during the second half of 2026 seeking approval for BRUKINSA plus rituximab as a frontline treatment for previously untreated mantle cell lymphoma.
If approved, the regimen could become one of the first chemotherapy-free first-line treatment options available for patients with this disease.
Understanding Mantle Cell Lymphoma
Mantle cell lymphoma is a relatively rare but aggressive subtype of B-cell non-Hodgkin lymphoma.
The disease develops when malignant B lymphocytes originating in the mantle zone of lymph nodes begin growing uncontrollably.
Although MCL accounts for only a small percentage of all non-Hodgkin lymphoma cases, it is generally considered one of the more challenging forms to treat due to its aggressive clinical behavior and tendency to relapse.
The disease most commonly affects older adults, many of whom have additional medical conditions that complicate treatment decisions.
Challenges of Current Standard Therapy
For many years, frontline treatment has relied primarily on chemoimmunotherapy regimens such as bendamustine plus rituximab.
While these therapies can produce meaningful responses, they are also associated with several significant drawbacks.
Chemotherapy frequently causes suppression of bone marrow function, resulting in reduced blood cell production.
Patients may experience prolonged immune suppression that increases susceptibility to infections, while cumulative toxicities can become especially problematic for elderly individuals.
These treatment-related complications often affect quality of life and may limit the ability of some patients to complete therapy.
A New Direction for First-Line Treatment
The MANGROVE study reflects a broader shift in oncology toward targeted therapies that selectively attack cancer cells while minimizing exposure to conventional chemotherapy.
Rather than enhancing chemotherapy with additional drugs, BeOne Medicines sought to determine whether targeted inhibition of Bruton’s tyrosine kinase using BRUKINSA could serve as the foundation of frontline treatment by itself.
The positive interim findings suggest that this strategy may successfully deliver durable disease control while reducing many of the burdens associated with chemotherapy.
If regulatory approvals are secured, the BRUKINSA plus rituximab regimen could offer physicians and patients a new standard of care that combines improved efficacy with a less intensive treatment approach, representing a major advancement in the management of newly diagnosed mantle cell lymphoma.
Source Link: https://www.businesswire.com/
